Sparavigna Adele, Tenconi Beatrice, De Ponti Ileana, La Penna Laura
DermIng srl, Clinical Research and Bioengineering Institute, Monza, MB, Italy.
Clin Cosmet Investig Dermatol. 2015 Apr 9;8:179-85. doi: 10.2147/CCID.S82859. eCollection 2015.
Acne is characterized by primary lesions on the face, chest, and back, and by a variety of other signs and symptoms. In particular, acne inflammatory lesions result from Propionibacterium acnes colonization and are of particular relevance as they can cause permanent scarring. Acne also causes significant psychological morbidity in affected patients. Products currently available for the treatment of acne include systemic and topical treatments. As these products can cause severe side effects, new, innovative therapies are needed. Farmaka Acne Cream (FAC) is a novel, film-forming cream developed to treat mild and moderate acne. In vitro studies have demonstrated that FAC is as effective as 5% benzoyl peroxide in inhibiting growth of P. acnes. In 32 subjects with mild or moderate acne, FAC reduced all the major signs and symptoms of the disease. These included itching, erythema, and scaling, as well as reductions in the numbers of papules, pustules, and open and closed comedones. Acne severity improved in 38% of subjects, while none worsened. FAC was found to be effective in controlling sebum secretion, and was non-comedogenic. Most subjects (90%) reported tolerability as good or very good, while clinical efficacy and cosmetic acceptability were judged as good. For assessment of contact sensitization and photosensitization, FAC was applied daily to the backs of 29 subjects in two symmetric areas for 10 days. Using a solar stimulator, one minimal erythema dose was delivered to one side of the back from days 11 to 13. The four different subareas of treated/untreated and irradiated/nonirradiated and combinations thereof were compared. No cases of contact sensitization or photosensitization were observed, and FAC is considered safe for use in intense sunlight. In vitro and in vivo studies provide evidence for the safety and clinical benefits of FAC, a promising candidate for the treatment of mild and moderate acne.
痤疮的特征是面部、胸部和背部出现原发性皮损，以及各种其他体征和症状。特别是，痤疮炎症性皮损是由痤疮丙酸杆菌定植引起的，尤为重要的是它们会导致永久性瘢痕形成。痤疮还会给受影响的患者带来严重的心理问题。目前可用于治疗痤疮的产品包括全身性和局部性治疗。由于这些产品可能会引起严重的副作用，因此需要新的创新疗法。Farmaka痤疮霜（FAC）是一种新型的成膜乳膏，用于治疗轻度和中度痤疮。体外研究表明，FAC在抑制痤疮丙酸杆菌生长方面与5%的过氧化苯甲酰一样有效。在32名轻度或中度痤疮患者中，FAC减轻了该疾病的所有主要体征和症状。这些体征和症状包括瘙痒、红斑、脱屑，以及丘疹、脓疱、开放性和闭合性粉刺数量的减少。38%的患者痤疮严重程度有所改善，无一例病情恶化。FAC被发现对控制皮脂分泌有效，且不具有致粉刺性。大多数受试者（90%）报告耐受性良好或非常好，而临床疗效和美容可接受性被评为良好。为了评估接触性致敏和光致敏情况，FAC每天涂抹在29名受试者背部的两个对称区域，持续10天。从第11天到第13天，使用太阳模拟器向背部一侧给予一个最小红斑量。比较了治疗/未治疗、照射/未照射及其组合的四个不同子区域。未观察到接触性致敏或光致敏病例，并且FAC被认为在强烈阳光下使用是安全的。体外和体内研究为FAC的安全性和临床益处提供了证据，FAC是治疗轻度和中度痤疮的一个有前景的候选药物。
